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INTRODUCTION
Lithium has been the major pharmacological treatment for
the management of recurrent bipolar illness for many years
(1). Both the combination therapy strategies with lithium
and lithium’s extremely narrow therapeutic window enhance
the potential for neurotoxicity (2). In fact, the vast majority
(75-90%) of patients receiving maintenance lithium therapy
become intoxicated at some point during the course of thera-
py (3). Lithium may induce multisystemic adverse and toxic
effects which might lead to severe and life-threatening com-
plications if it goes unrecognized.
More than 50% of the patients on lithium treatment re-
ceived at least one concomitant antipsychotic medication dur-
ing the course of their treatment (4). The first report of neuro-
toxicity due to interaction between lithium and haloperidol
was reported in 1974 (5). Afterwards, several other case reports
which revealed delirium and extrapyramidal signs following
use of lithium-antipsychotic drugs (e.g. chlorpromazine, tri-
fluperazine, thioridazine, etc.) combination have also been
published (6-8).
In addition to interaction with typical antipsychotics, there
are also several recent reports indicating increased adverse
effects associated with concomitant administration of atypi-
cal antipsychotics with lithium in clinical practice (9-12). In
this article, we reported a patient with a diagnosis of bipolar
I disorder  who developed severe delirium and extrapyrami-
dal signs after initiation of lithium-olanzapine combination
therapy, and discussed confounding factors and the manage-
ment of lithium intoxication.
CASE REPORT
A 62-yr-old woman with a diagnosis of bipolar disorder,
was referred to our emergency service with symptoms of alter-
ation in mental status, psychomotor slowness, difficulty in
walking, and tremor in limbs. The patient had started to
experience bipolar episodes twenty years ago and has been
on lithium therapy continuously during last seven years. At
the time of her current admission to our hospital, she was
receiving 900 mg/day lithium and 5 mg/day olanzapine. Her
physician reported that in last 12 months, the patient had
neither positive symptoms of bipolar disorder nor lithium
toxicity symptoms. There were no occupational, interperson-
al or marital problem during this follow-up period. Previous
month, plasma level of lithium was examined within normal
range (0.81 mM/L).
Physical examination on current admission revealed an
afebrile and lethargic woman. Her blood pressure was 120/70
mmHg with a pulse rate of 86/min and respiration 16/min.
In her mental status examination, the patient’s response to
simple verbal commands was well but disorientation to place
and time was prominent. She also had loosened associations
and rhyming. The neurological examination showed clear
upward gaze palsy without a supranuclear component, severe
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bradykinesia, severe rigidity of the forelimbs with positive
cogwheel, and rest and postural tremor with mild amplitude
and frequency of 4-5 Hz in all limbs, predominantly on the
right side. 
At admission our emergency ward, all of the drugs she used
were discontinued. The initial plasma level of lithium at the
time of admission was 3.0 mM/L. Serum laboratory studies
revealed a mild increase in number of white blood cells (8,500
cells/ L blood), erythrocyte sedimentation rate of 28 mm/hr.
Fasting blood glucose level was 114 mg/mL, and acetone and
ketone levels in urine were negative. She had a prerenal azote-
mia with serum creatinine level of 1.5 mg/dL, urea level of
84 mg/dL and a blood urea nitrogen level of 32 mg/dL. Crea-
tinine phosphokinase (CPK) level was 34 U/L. Serum sodium
(Na+), potassium (K+) and chloride (Cl-) levels were 135 mM/L,
4.8 mM/L and 117 mM/L respectively. 
Afterwards, the patient’s volume-electrolyte balances (5,000
mL/day) and diuresis were examined carefully. She was man-
aged with 0.9% saline and a good diuresis was established.
Other routine laboratory studies and a urine toxicology screen
were negative. The electrocardiogram on admission showed
sinusoidal bradycardia and antero-posterior chest radiography
was normal. Cranial computed tomography did not reveal
any pathology except age-related cortical atrophy.
Her detailed history as acquired from her relatives avail-
able has shown that she had been hospitalized for four times
till the age of 55 yr. Only at this age could she be diagnosed
as bipolar disorder and initiated lithium therapy. Severe manic
episodes with mood-congruent psychotic symptoms domi-
nated the mood episodes requiring the hospitalizations. There
were also milder depressive episodes during which treatment
was conducted at outpatient clinics. After the initiation of
lithium therapy with a dose of 900 mg/day, the patient re-
mained asymptomatic for seven years. She did not necessi-
tate any other concomitant antipsychotic drug or anxiolytic
drug during these period.  
Another significant point in her history was the deterio-
ration in her mental status last year  after addition of a typi-
cal antipsychotic (chlorpromazine 200 mg/day) to her thera-
py in order to lessen her abrupt insomnia. The patient was
brought to emergency ward with signs and symptoms of
lethargy, confusion and hyperprexia ten days after initiation
of chlorpromazine 200 mg per day. At the examination, she
had increased muscle tone of upper limbs and paresia of lower
limbs. Laboratory tests including examination of blood, urine,
cerebrospinal fluid, protein electrophoresis, electromyography,
electroencephalography, enzymes of muscles, kidney func-
tions, and plasma level of lithium (0.69 mmol/L) were with-
in normal range. The cranial magnetic resonance imaging
of our patient revealed multiple microlacunar infarcts which
were not congruent with the level of the clinical picture. The
discontinuation of all drugs resulted in complete remission
within 72 hr. Later lithium therapy were re-initiated with-
out recurrence of any mentioned clinical symptoms. She did
not receive any other concomitant drugs till three weeks before
admission. A physician prescribed olanzapine 5 mg/day due
to her increased suspiciousness towards her neighbors and
possible appearance of auditory hallucinations. No other spe-
cific information could be obtained concerning the need for
adding olanzapine therapy from the patient files.  
At current admission, approximately 24 hr later, the patient
became more alert but, psychomotor hyperactivity and abnor-
mal extrapyramidal symptoms were keeping on. Two days
later, the patient’s lithium level had decreased to 1.81 mM/L
and her confusion also lessened. At the end of the fourth day,
the patient’s lithium level was 0.32 mM/L. Her dysarthria
had improved dramatically, involuntary movements of limbs
and rigidity lessened. At fifth day, the patient became mobile,
the neurological symptoms except perioral dyskinesia were
almost completely resolved. To prevent the recurrence of bipo-
lar disorder, carbamazepine was started with a slow dose escala-
tion (600 mg/day) at the end of the first month and its plasma
level was titrated to 6.5  g/L on control. The patient showed
a rapid and dramatic recovery. At discharge, she was complete-
ly orientated with no further thought disturbances. Examina-
tion three months later revealed that her mood was euthymic
with appropriate affect. There was no evidence of hallucina-
tions or delusions, but perioral dyskinesia.
DISCUSSION 
In lithium intoxication, the patients may present with gas-
trointestinal and cerebellar manifestations with organic psy-
chopathological symptoms such as confusion, disorientation,
and alterations of consciousness. Although extrapyramidal
symptoms have also been reported with lithium alone (13, 14),
she had well tolerated chronic lithium therapy for approxi-
mately seven years and the symptoms above mentioned became
apparent only after initiation of lithium-olanzapine combi-
nation. Therefore, any side effect of lithium alone does not
explain this clinical picture. In several case reports, extrapyra-
midal system symptoms (e.g. tremor, orofacial or whole body
movements and cogwheel rigidity) were observed after lithi-
um-antipsychotic combination therapy (4, 8, 15). Normal
motor behavior results from a relative balance between the
dopaminergic and cholinergic systems. Extrapyramidal symp-
toms are induced whenever there is an imbalance between
these two neurotransmitter systems. Lithium is known to de-
crease the amount of dopamine in rat striatum and limbic
forebrain (16). The clinical presentation of extrapyramidal
system signs is commonly observed after the combined treat-
ment of lithium with an antipsychotic drug. Thus, we thought
that concomitant administration of antipsychotics with lithi-
um should be examined more carefully for explaining the
delirious clinical symptoms in our case.  
After discontinuation of lithium-olanzapine combination,
our patient has had perioral dyskinesia for three months. Con-cerning the distribution of lithium in the brain, animal stud-
ies suggest that, after chronic treatment, lithium is prefer-
entially concentrated in the striatum and the hypothalamus
as compared to the cerebellum and the cortex. Clinical obser-
vations suggest that the combination of lithium and dopamin-
ergic blocking agents (e.g. haloperidol) while having poten-
tiating action, may give rise to persisting neurotoxicity (severe
dyskinesias presenting as orofacial or whole body movements)
(4). Prakash et al. also report that lithium-antipsychotic neu-
rotoxicity appeared to be persistent in 10.5% of the patients
(15). These findings could explain perioral dyskinesia in our
patient.
The possibility of ingestion of overdose must be ruled out.
In our case, there was no sign indicating ingestion of over-
dose as an accident or as a suicidal attempt. Generally, chron-
ic intoxication are more severe, as tissue levels and therefore
end organ toxicity are higher. In acute ingestion, until equi-
libration between plasma and tissue occurs, serum lithium
levels poorly reflect tissue levels and therefore correlate poor-
ly with toxicity. Because of the slow equilibration, patients
with acute overdose are usually asymptomatic unless their
presentation is significantly delayed (2). Toxic effects could
be observed at a serum lithium concentration of about or more
than 1.5 mM/L. However, severe clinical toxicity among
patients who have therapeutic lithium levels were also report-
ed (4, 17, 18). It is hypothesized that antipsychotics, in par-
ticular phenothiazines, increase lithium influx in red cells (4).
It appears that the brain lithium level is more closely corre-
lated with RBC concentration than with plasma concentra-
tion. Increased levels of lithium in tissues may be related to
neurotoxic effects observed during combined therapy. In light
of these data, we determined the patient’s clinical picture of
the confusion and paraparesia at normal lithium level in the
previous year as “neurotoxicity or vulnerability to develop the
neurotoxicity”. In our case, those symptoms became apparent
after the initiation of a typical antipsychotic drug, chlorpro-
mazine, with lithium therapy last year. A few studies sug-
gested advanced age, being female, combination with an anti-
psychotic drug, and presence of acute psychotic symptoms
as confounding factors for developing lithium toxicity (18-
20). Especially for economic, social and physiological rea-
sons, the elderly are at particular risk. This patient also had
most of these factors in developing lithium toxicity in com-
bination therapy.
In current practice, atypical antipsychotics are generally
preferred over conventional antipsychotics. One of them, olan-
zapine is a well tolerated atypical antipsychotic (21). In vitro
data indicate that olanzapine is metabolized by cytochrome
P450 (CYP) isozymes such as CYP1A2 and CYP2D6. Olan-
zapine does not appear to inhibit CYP isozymes (22). No clini-
cally significant metabolic interactions were reported between
olanzapine and lithium (21). It is apparent that symptoms
of lithium neurotoxicity developed when our patient was
taking both lithium-olanzapine (current therapy) and lithi-
um-chlorpromazine (previous therapy) combination thera-
pies. Thus, we could speculate that development of neuro-
toxicity or neurotoxic symptoms as a result of typical antipsy-
chotic drug-lithium combination might aggravate the vul-
nerability of patients to develop neurotoxicity due to atypi-
cal antipsychotic drug-lithium combination. In patients hav-
ing history of lithium-neuroleptic toxicity, atypical antipsy-
chotic drug-lithium combination might be not a safe treat-
ment choice. 
In lithium neurotoxicity, several differential diagnosis have
to be taken into consideration. Among those, delirium due
to hyperglycemic hyperosmolar nonketotic coma was exclud-
ed in our case, because she had no history of diabetes and fast-
ing blood level was within normal range. There are several
reports in literature developing diabetic ketoacidosis associ-
ated with olanzapine treatment alone (23-25). Our patient’s
urine acetone and ketone levels were also negative making
us completely exclude this possibility. Delirium may present
after cerebrovascular diseases. But this condition generally
associated with additional neurological findings such as motor
and sensory deficits, cranial nerve palsy, etc (26). In our patient,
there were no lateralized neurological findings. In differen-
tial diagnosis, neuroleptic malignant syndrome (NMS) was
also considered. NMS is a life-threatening syndrome charac-
terized by prominent extrapyramidal and autonomic symp-
toms (27). However, our patient showed neither hyperpyrexia
nor abnormal laboratory findings including leukocyte count,
CPK and liver enzymes which are pathognomic findings for
this diagnosis. 
As a conclusion, there is a possibility of a rare but serious
interaction between lithium and antipsychotic drugs. Lithi-
um therapy requires close and regular clinical observations,
and serum concentration monitoring to avoid any unexpect-
ed changes in lithium levels which might sometimes result
in intoxication. Because serum lithium levels do not always
reflect correctly intracellular concentrations, a normal lithi-
um level does not exclude the possibility of lithium intoxi-
cation. It is useful for physicians and patients to keep in mind
that those of the confounding and vulnerability factors and
especially concomitant administration of antipsychotics might
increase the risk of lithium toxicity.
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